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 ABSTRACT  
 
Background: Deletion of the Complement Factor H Related 1 (CFHR1) gene is a 
consequence of non-allelic homologous recombination and has been reported to be more 
frequent in atypical hemolytic uremic syndrome (aHUS) patients than in the normal 
population. Therefore, it is considered a susceptibility factor for the disease. Atypical HUS is 
associated with hereditary or acquired abnormalities that lead to uncontrolled alternative 
pathway complement activation. We tested the CFHR1 deletion for association with aHUS in 
a population of French aHUS cases and controls. Furthermore, we examined the effect of the 
deletion in the context of known aHUS risk factors.  
Methodology and findings: 177 aHUS patients and 70 healthy donors were studied. The 
number of CFHR1 alleles was quantified by Multiplex Ligation-dependant Probe 
Amplification (MLPA). The frequency of the deleted allele was significantly higher in aHUS 
patients than in controls (22.7% versus 8.2%, P<0.001). The highest frequency was in the 
subgroup of patients exhibiting anti-Factor H (FH) auto-antibodies (92.9%, P<0.0001 versus 
controls) and in the group of patients exhibiting a Factor I (CFI) gene mutation (31.8%, 
P<0.001 versus controls). The CFHR1 deletion was not significantly more frequent in the 
cohort of aHUS patients when patients with anti-FH IgG or CFI mutation were excluded. 
Conclusions: The high frequency of CFHR1 deletion in aHUS patients is restricted to the 
subgroups of patients presenting with anti-FH auto-antibodies or, to a lesser degree, CFI 
mutation. These results suggest that the CFHR1 deletion plays a secondary role in 
susceptibility to aHUS.  
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INTRODUCTION 
 
Atypical, or non-Shigatoxin-associated haemolytic uremic syndrome (aHUS, 
OMIM#235400), is a rare form of thrombotic microangiopathy that principally affects the 
kidneys’ microvasculature, leading to severe acute renal failure. Genetic susceptibility factors 
have been identified in almost 60% of aHUS cases. These factors are genetic abnormalities 
leading to loss-of-function proteins encoded by  genes involved in the complement alternative 
pathway regulation: Factor H (CFH), Membrane Cofactor Protein (MCP or CD46) and Factor 
I (CFI) [1].  Recently, other mutations have been found that lead to gain-of-function proteins 
encoded by genes for the C3 convertase components, C3 or factor B (CFB) [2, 3]. In addition, 
a genetic abnormality has been identified that is due to unequal recombination in the RCA 
(Regulators of Complement Activation) locus, which comprises several genes encoding 
proteins implicated in regulation of complement activation. CFH and the genes encoding the 
five Complement Factor H Related proteins (CFHR1-CFHR5) exhibit a high degree of 
sequence homology. There are two highly homologous sequences with long interspersed 
nuclear elements (retrotransposons) within this locus, which favours the occurrence of 
unequal recombinations [4]. This mechanism leads to the production of a hybrid protein 
secondary to the fusion of the CFH gene encoding factor H and CFHR1 gene, leading to a 
Factor H functional deficiency [5]. 
Finally, aHUS may occur in the context of an auto-immune disease, with the development of 
anti-FH auto-antibodies leading to an acquired FH deficiency [6, 7]. All these abnormalities 
lead to a hyperactive alternative pathway C3 convertase. 
In addition to these causative factors, several studies have identified additional susceptibility 
factors that consist of genetic polymorphisms more frequently observed in aHUS patients than 
in the control population. These include single nucleotide polymorphisms (SNP) identified in 
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the CFH, MCP or C4BP genes [8, 9] or a deletion of CFHR1 and CFHR3 genes resulting 
from an unequal recombination occurring outside the coding sequences of CFH and CFHR1 
[4]. This deletion of CFHR1-CFHR3 has been reported to be associated with aHUS and also 
to be protective against age-related macular degeneration (AMD; OMIM#603075) [10, 11]. 
Recently, Jozsi et al. reported a high frequency of lack of circulating CFHR1 and CFHR3 
proteins in a group of patients with the auto-immune form of aHUS [7], which could be due to 
the same genetic mechanism. 
The aim of our study was to determine the frequency of CFHR1 deletion in a French cohort of 
aHUS patients and to correlate the deleted allele and the deletion homozygosity frequencies 
with other susceptibility factors. We show that the high frequency of CFHR1-CFHR3 deletion 
found in aHUS patients is due to a particularly high frequency of the homozygous deletion in 
the subgroup of patients with anti-FH auto-antibody – associated aHUS and, to a lesser 
degree, a CFI mutation. 
 
MATERIALS AND METHODS 
 
Participants 
 
All patients of the French cohort of aHUS were studied between 2002 and 2007. The criteria 
for the diagnosis of HUS were thrombocytopenia (<150 G/l), renal dysfunction associated 
with acute anemia and fragmented red cells on blood film. None of the patients exhibited 
biological criteria of a shigatoxin productive bacteria infection. Patients who developed the 
illness in a context of infectious disease (HIV, Mycoplasma pneumoniae, Borderellia 
pertussis, Varicellavirus), hemopathy, solid neoplasia or organ transplantation (except renal 
graft) were excluded. The cohort consisted of 86 children and 91 adults. Informed consent 
was obtained from each patient (or parents in the case of children), and the study was 
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approved by the Ethics Committee of the Assistance Publique-Hôpitaux de Paris. The control 
group comprised 70 French healthy blood donors. 
 
Complement assays 
 
Measurement of CH50 activity in EDTA plasma samples was performed as previously 
described. Plasma concentrations of the complement components C4, C3 and Factor B (FB) 
antigens were measured by nephelometry (Dade Behring, Paris La Defense, France). Factor H 
and Factor I antigen concentrations were measured by sensitive ELISA methods and CD46 
membrane expression was determined by flux cytometry as previously described [12]. 
Presence of anti-FH IgG was detected by using an ELISA method as previously described [6].  
 
Genomic CFH, CFI and MCP DNA sequencing 
For genetic analysis, genomic DNA was extracted from peripheral blood cells and amplified 
by Polymerase Chain Reaction (PCR) using oligonucleotides flanking each exon of the CFH, 
FI and MCP genes. Primer sequences, length of the PCR-amplified fragments and 
temperatures of hybridization used for each reaction and direct DNA sequencing procedure 
have been previously described [12]. Samples were run on the ABI PRISM 3730 Analyser 
Capillary electrophoresis system (Applied Biosystems) and sequence analyses were 
performed using the Sequencher® software. 
 
Multiplex Ligation-dependant Probe Amplification (MLPA) 
The MLPA reaction was performed as previously described [13]. Briefly, 50 ng DNA was 
incubated with 2 fmol of each set of 2 synthetic probes that hybridize immediately adjacent 
targets at the sequences of interest. Sequences of probes were designed to determine dosage 
for exon 5 of CFHR1 and exon 23 of CFH along with control probe C1INH exon 8. In some 
patients, dosage for exon 3 of CFHR3 was determined. Hybridization sequences were : 
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CFHR1a : 5’-GACTGACTGAGGACAGCCAAACAGAAGCTTTATTT-3’, CFHR1b : 5’-
GAGAACAGGTGAATCAGCTGAATTTG-3’, CFHex23a : 5’-
GGACAGCCAAACAGAAGCTTTATTC-3’, CFHex23b : 5’-GAGAACAGGTGAATCAG 
TTGAATTTG-3’, C1Iex8a : 5’-CTGAAGGGCTTCACGACCAAAGGTGT-3’, C1Iex8b : 
5’-CACCTCAGTCTCTCAGATCTTCCCAC-3’, CFHR3a : 5’-GTTTGTACAGGGT 
AACTCTAC-3’, CFHR3b : 5’-AGAAGTTGCCTGCCATCCTGGC-3’. Probes contained 
binding sites for primers used for MLPA and a stuffer sequence used to determine a unique 
length of each amplified probe product. Right-hand probes were 5' phosphorylated (MWG, 
Roissy, France). MLPA reagents were purchased from MRC Holland (MRC Holland, 
Amsterdam, The Netherlands), and the reaction was carried out according to the 
manufacturer's recommended protocol. Amplified products were diluted 1/10 in deionised 
formamide (Applied Biosystems, Courtaboeuf, France) with a ROX 400HD (Applied 
Biosystems, Courtaboeuf,France) internal size standard. Samples were run on the ABI PRISM 
3730Analyser Capillary electrophoresis system (Applied Biosystems, Courtaboeuf, France). 
Peaks and areas for each sample were determined using Genemapper v4.0 Software (Applied 
Biosystems, Courtaboeuf, France) and dosage quotients were calculated. 
Statistical analysis 
The statistical analysis used the Chi square methods. 
 
RESULTS 
 
We used MLPA (Multiplex Ligation-dependant Probe Amplification) reaction to quantify the 
number of allele copies of CFHR1 gene (Figure 1) in a French cohort of 177 patients with 
aHUS.  
A genetic susceptibility factor was identified in 117 (66%) of patients. A genetic abnormality 
implicating CFH (comprising one CFH/CFHR1 hybrid gene), CFI or MCP was found in 
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21.5%, 12.4% and 9.6% of patients, respectively. In addition, sixteen (9%) patients had a C3 
mutation and seven (4%) patients had combined mutations implicating two or three genes. 
Some of the mutations identified have been reported previously [2, 12, 14, 15, 16, 17]. 
Finally, fourteen (7.9%) patients presented with an auto-immune form of aHUS with anti-
Factor H auto-antibodies. 
A genomic deletion of CFHR1 was found in 56 (31.6%) patients. This deletion was 
homozygous in 12.4 % (n=22) or heterozygous in 19.8% (n=35) of patients, as determined by 
the number of CFHR1 copies (Table 1).  
 
Table 1 : Determination of the number of CFHR1 alleles according the previously identified 
susceptibility factor in the French aHUS cohort (n=177 patients). 
 
% (n) 0 allele 1 allele 2 alleles 
Total cohort 12.4 (22) 19.8 (35) 68 (120) 
No factor identified 4.7 (3) 26.6 (17) 68.8  (43) 
CFH mutation 2.6 (1) 10.5  (4) 86.8 (33) 
CFI mutation 18.2 (4) 27.3 (6) 54.5 (12) 
MCP mutation 0 6.25 (1) 94 (16) 
C3 mutation 6.3 (1) 31 (5) 62.5 (10) 
Combined 
mutations 
0 29 (2) 71 (5) 
Anti-FH IgG 93 (13) 0 7 (1) 
Normal 
Population 
2.8  (2) 11.4 (8) 85.7 (60) 
 
 
Thus, the calculated frequency of the deleted allele was 22.7%. In the control population, a 
genomic deletion was found in ten controls (14.3%, homozygous in two and heterozygous in 
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eight), giving an allele frequency of 8.2%. Thus, the CFHR1 deleted allele frequency was 
significantly higher in aHUS patients as compared to controls (22.7% versus 8.2%, P<0.001). 
The distribution of the deleted allele in our cohort of aHUS patients, according to the 
susceptibility factor(s) identified in each patient, is depicted in Table 2.  
 
Table 2 : Frequency of a CFHR1 deleted allele according to the susceptibility factor and 
comparison of each subgroup with the control population using a χ2 
 test. 
 
 
Frequency of CFHR1 
deleted allele (%) in 
each subgroup 
Chi 2 P 
Total cohort 22.3 12.6 P= 0.0003 
No factor identified 18.3 3.04 p = 0.08 
CFH mutation 7.9 0.03  P = 0.9  
FI mutation 31.8 14.9 P = 0.0001 
MCP mutation 2.9 1.25 P=0.3 
C3 mutation 21.9 4.69 P=0.03 
Combined mutations 14.3 0.5 P=0.5 
Anti-FH IgG  92.9 94.7 P<0.0001 
Cohort without anti-
FH IgG cases 
16.3 4.8 P = 0.02 
Cohort without anti-
FH IgG nor FI cases 
13.8 2.43 P = 0.12 
Control Population 8.6 -  
 
 
The frequency of CFHR1 deletion was particularly high in the subgroup of patients presenting 
with an auto-immune form of aHUS, in which the allele frequency was 92.9% (χ2 = 94.7, 
P<0.0001). Among the patients with a genetic abnormality of the complement genes, only 
 10
those exhibiting a CFI mutation (31.8 %, P<0.001) or a C3 mutation (21.9%, P=0.03) showed 
a significantly higher frequency of the deleted allele compared to controls. In the other 
subgroups, no significant difference was observed compared to controls. In patients in whom 
no genetic factor was identified, the frequency of the deleted allele was significantly higher 
than in the control population (18.3%, P=0.02). On the contrary, the frequency of the deleted 
allele was lower in subgroups of patients exhibiting a genetic abnormality in the CFH and 
MCP genes than in the control group (7.9% and 2.9% respectively, versus 8.6% in controls) 
but did not confer a significant protective status (OR=0.75, 95% CI= 0.25-2.21, P>0.1) 
(Figure 2). After exclusion of patients with anti-FH IgG and CFI mutation, the frequency of 
the CFHR1 deletion in the cohort of aHUS patients was not significantly different from the 
frequency in the control group. 
We then hypothesized that CFHR1 deletion homozygosity alone could be a susceptibility 
factor. Therefore, we studied the distribution of homozygous CFHR1 deletion in the different 
subgroups of patients according to susceptibility factor(s) (Table 3).  
 
Table 3 : Frequency of a homozygous CFHR1 deletion according to the susceptibility factor 
and comparison of each subgroup with the control population using a χ2 test. 
 
 
Frequency of 
homozygous 
CFHR1deletion (%) 
in each subgroup 
Chi 2 P 
Total cohort 12.4 5.24 P= 0.022 
No factor identified 4.8 0.33 NS 
CFH mutation 2.6 0.002  NS  
FI mutation 15 6.45 P = 0.011 
MCP mutation 0 0.50 NS 
C3 mutation 6.3 0.31 NS 
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Combined mutations 0 0.20 NS 
Anti-FH IgG  92.9 64.45 P<0.0001 
Cohort without anti-
FH IgG cases 
5.5 0.77 NS 
Cohort without anti-
FH IgG nor FI cases 
3.5 0.07 NS 
Control Population 2.9 -  
 
 
The frequency of homozygous CFHR1 deletion was higher than in the control population 
only in the subgroup of patients with CFI mutation (15% versus 2.9% in controls, P = 0.011) 
and in patients exhibiting anti-FH auto-antibodies (92.9% versus 2.9% in controls, P<0.0001). 
In this last subgroup, 13 of 14 patients exhibited homozygous CFHR1 deletion. The 
frequency of the deletion homozygosity in the subgroup of patients with no known 
susceptibility factor was not significantly higher than in controls (5.5% versus 2.9%, OR = 
1.96, 95% CI 0.32-11.8, P>0.1) (Figure 2). 
We then performed CFHR3 allele quantification by MPLA in the subgroup of patients with 
anti-FH IgG auto-antibodies. With one exception, a complete absence of the CFHR3 gene was 
observed in all CFHR1 deletion patients.  
 
DISCUSSION 
 
In our study, the deleted allele’s frequency is 8.2% and 22.7% in the normal and the study 
population, respectively, with a deletion homozygosity ‘s frequencies of  2.9% and 12.4%. 
These results are in accordance with the previously reported frequencies in healthy controls 
and in aHUS patients. The frequency of the CFHR1 homozygous deletion in different control 
populations has been estimated at 2% to 5.7% [4, 10, 18]. Zipfel et al. have reported a 
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frequency of homozygous deletion of CFHR1 in 16% and 10.6% of aHUS patients from the 
Jena and Newcastle cohorts, respectively [4]. In addition, Hughes et al. have reported the 
presence of the deleted allele in 20% of chromosomes in a normal but elderly population 
(n=170). The frequency was significantly lower (8%) in an age-matched population (n=173) 
affected by AMD, suggesting that the CFHR1 deletion confers protection against AMD (OR 
0.4 (95%CI,0.3-0.5) [11] 
The fact that the CFHR1 deletion occurred at a higher frequency in the subgroups of patients 
exhibiting a mutation in a gene located outside the RCA locus (CFI, C3) suggests that a 
defect affecting one gene in the RCA locus might be necessary for the development of the 
disease or play a role for its  severity. These roles remain to be elucidated. 
The deletion homozygosity is particularly high in the subgroup of patients exhibiting anti-FH 
auto-antibodies. This group comprises eleven children (age at disease onset : 7 months –13 
years, median : 9 years old, five males and six females) and three adults (median age at 
disease onset : 28 years old, all males). The deletion affects the CFHR1 and CFHR3 genes. 
These results confirm that the homozygous deletion of CFHR1 and CFHR3 genes is the 
genetic mechanism responsible for the absence of  circulating CFHR1 and CFHR3 observed  
in the particular group of patients exhibiting an auto-immune form of aHUS [7].  
The particular correlation that exists between the presence of a homozygous deletion of 
CFHR1 and CFHR3 genes and the development of anti-FH auto-antibodies reveals that most, 
if not all, patients with an “acquired” form of aHUS share the same homozygous genetic 
polymorphism. This genetic predisposition seems to be necessary but not sufficient for 
developing the disease, as this homozygous deletion is also observed in controls. The 
mechanisms responsible for development of auto-antibodies against FH are not yet 
understood. Our results suggest a particular role of CFHR1 and CFHR3 proteins in the 
development of this auto-immunity. 
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In the group of patients without genetic or acquired abnormality affecting the alternative 
pathway (n = 55), the frequency of the deletion homozygosity is not different than in the 
control population conferring a non significant risk for the disease. These results suggest that 
in our study population, the CFHR1 deletion does not represent a susceptibility factor for 
aHUS by itself.  
In conclusion, the high frequency of CFHR1 deletion observed in our aHUS patients is due to 
the presence of CFHR1 homozygous deletion in only two categories of patients: those with 
anti-FH auto-antibodies associated HUS and, to a lesser degree, those with a CFI mutation. 
The results highlight the link between the CFHR1 and CFHR3 homozygous deletion and the 
development of anti-FH auto-antibodies.  
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FIGURE LEGEND:  
 
Figure 1 : Risk for developing aHUS associated with CFHR1 deletion homozygosity. 
The Odds Ratio values are represented by circles. The risk was significant in the subgroups of 
patients with anti-FH auto-antibodies and CFI mutation. In 2 groups of patients, no Odds 
Ratio may be calculated (N/A: no available) as no CFHR1 homozygous deletion was found in 
these groups.
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